目的 探究奧美沙坦酯聯(lián)合拉貝洛爾治療原發(fā)性高血壓患者的臨床效果。方法 選取2023年2月—2024年2月在首都醫(yī)科大學(xué)宣武醫(yī)院診治的原發(fā)性高血壓患者141例，隨機分為對照組（70例）和治療組（71例）。對照組患者口服鹽酸拉貝洛爾片，100 mg/次，2次/d。治療組在對照組基礎(chǔ)上口服奧美沙坦酯片，20 mg/次，1次/d。兩組患者均進(jìn)行為期8周的治療。觀察兩組患者臨床療效，比較治療前后兩組患者血壓水平、中醫(yī)證候評分、杜氏高血壓生活質(zhì)量量表評分、反應(yīng)性充血指數(shù)（RHI）、血清內(nèi)皮素-1（ET-1）和白細(xì)胞介素-6（IL-6）。結(jié)果 經(jīng)治療，對照組和治療組患者臨床總有效率分別為82.86%、95.77%，兩組比較差異具有統(tǒng)計學(xué)意義（P＜0.05）。經(jīng)治療，兩組患者收縮壓、舒張壓及脈壓差均明顯低于治療前（P＜0.05），且治療組明顯低于對照組（P＜0.05）。經(jīng)治療，兩組患者中醫(yī)證候評分均大幅度下降，杜氏高血壓生活質(zhì)量量表評分均明顯上升（P＜0.05），且治療組患者的各項評分改善程度均好于對照組（P＜0.05）。經(jīng)治療，兩組患者RHI水平均較治療前明顯升高，而血清ET-1和IL-6水平均較治療前明顯降低（P＜0.05），且治療組患者的各項指標(biāo)改善程度均優(yōu)于對照組（P＜0.05）。結(jié)論 奧美沙坦酯聯(lián)合拉貝洛爾治療原發(fā)性高血壓療效顯著，不僅能夠顯著降低患者的血壓水平，改善臨床癥狀，同時還能夠改善患者生活質(zhì)量并促進(jìn)內(nèi)皮功能和血清學(xué)指標(biāo)的修復(fù)。

Objective To investigate the effectiveness of olmesartan medoxomil combined with labetalol in treatment of primary hypertension. Methods Patients (141 cases) with primary hypertension in Xuanwu Hospital Capital Medical University from February 2023 to February 2024 were randomly divided into control (70 cases) and treatment (71 cases) group. Patients in the control group were po administered with Labetalol Hydrochloride Tablets, 100 mg/time, twice daily. Patients in the treatment group were po administered with Olmesartan Medoxomil Tablets on the basis of the control group, 20 mg/time, once daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical evaluations were evaluated, the blood pressure levels, the traditional Chinese medicine syndrome score and Du's hypertension quality of life scale score, and the levels of RHI, ET-1, and IL-6 in two groups before and after treatment were compared. Results After treatment, the total clinical effective rates in the control group and treatment group were 82.86% and 95.77%, respectively, and the difference between the two groups was statistically significant (P < 0.05). After treatment, the systolic blood pressure, diastolic blood pressure, and pulse pressure differences in two groups were significantly lower than before treatment (P < 0.05), and the pressures in the treatment group was significantly lower than that in the control group (P < 0.05). After treatment, the TCM syndrome scores in two groups were significantly decreased, and the scores of Du's hypertension quality of life scale score were significantly increased (P < 0.05), and the improvement of various scores in the treatment group was better than that in the control group (P < 0.05). After treatment, the RHI levels in two groups were significantly higher than before treatment, while the serum ET-1 and IL-6 levels were significantly lower than before treatment (P < 0.05), and the improvement of various indicators in the treatment group was better than that in the control group (P < 0.05). Conclusion Olmesartan medoxomil combined with labetalol is highly effective in treating essential hypertension, which can significantly reduce blood pressure, improve symptoms, enhance quality of life, facilitate endothelial function recovery, and reduce serum biomarkers.

R971